Immunogenicity and tolerability of a pandemic influenza A virus vaccine-H1N1, administered sequentially or simultaneously with a seasonal influenza virus vaccine [liposomal], for the prevention of pandemic and seasonal influenza virus infections in HIV-infected children and adolescents

Trial Profile

Immunogenicity and tolerability of a pandemic influenza A virus vaccine-H1N1, administered sequentially or simultaneously with a seasonal influenza virus vaccine [liposomal], for the prevention of pandemic and seasonal influenza virus infections in HIV-infected children and adolescents

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2011

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary) ; Influenza virus vaccine liposomal (Primary) ; MF 59
  • Indications Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 18 Feb 2011 New trial record
    • 31 Dec 2010 Results published in Vaccine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top